Swedish Orphan Biovitrum AB (publ) (SWOBY)

Market Cap	10.34B
Revenue (ttm)	2.61B
Net Income (ttm)	394.51M
Shares Out	n/a
EPS (ttm)	1.14
PE Ratio	26.21
Forward PE	19.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	302
Average Volume	975
Open	15.43
Previous Close	n/a
Day's Range	15.43 - 15.43
52-Week Range	12.20 - 17.20
Beta	0.23
RSI	52.73
Earnings Date	Jul 16, 2025

About SWOBY

Swedish Orphan Biovitrum AB (publ), a biopharma company, provides medicines in the areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. The company operates through three segments: Haematology, Immunology, and Specialty Care. It offers Alprolix for haemophilia B; ALTUVOCT for the treatment and prophylaxis of bleeding in patients with haemophilia A; Aspaveli/Empaveli for treating adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet for the treatment of immune thrombocy...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1939
• Employees: 1,806
• Stock Exchange: OTCMKTS
• Ticker Symbol: SWOBY

Financial Performance

In 2024, SWOBY's revenue was 26.03 billion, an increase of 17.65% compared to the previous year's 22.12 billion. Earnings were 3.89 billion, an increase of 61.27%.

Financial numbers in SEK